Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
22
3
2019
medline:
25
7
2020
entrez:
22
3
2019
Statut:
ppublish
Résumé
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda
Identifiants
pubmed: 30895564
doi: 10.1007/s40273-019-00792-7
pii: 10.1007/s40273-019-00792-7
pmc: PMC6713293
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
1195-1207Subventions
Organisme : Department of Health
ID : 16/119/02
Pays : United Kingdom
Références
Pharmacoeconomics. 2017 Dec;35(12):1287-1296
pubmed: 28849538
Bone Marrow Transplant. 2017 Mar;52(3):452-454
pubmed: 28092356
Br J Haematol. 2017 Nov;179(3):471-479
pubmed: 28857136
Health Aff (Millwood). 2008 Nov-Dec;27(6):1642-53
pubmed: 18997223
Value Health. 2013 Jul-Aug;16(5):703-19
pubmed: 23947963
Pharmacoeconomics. 2010;28(9):699-709
pubmed: 20629473
Value Health. 2012 May;15(3):570-9
pubmed: 22583469
Pharmacoeconomics. 2019 Oct;37(10):1195-1207
pubmed: 30895564
Ann Oncol. 2016 Jul;27(7):1317-23
pubmed: 27091808
BMJ. 2017 Oct 4;359:j4530
pubmed: 28978555
Value Health. 2009 Jul-Aug;12(5):739-49
pubmed: 19508655
Leuk Lymphoma. 2015 Jun;56(6):1839-45
pubmed: 25284490
Appl Health Econ Health Policy. 2018 Aug;16(4):429-432
pubmed: 29808296
Bone Marrow Transplant. 2015 Sep;50(9):1241-9
pubmed: 26076127
J Clin Epidemiol. 2019 Jan;105:50-59
pubmed: 30236484
Health Technol Assess. 2016 Apr;20(26):1-48
pubmed: 27049841